Low rate of recurrence of Helicobacter Pylori infection in spite of high clarithromycin resistance in Pakistan

BMC Gastroenterology

Rashida Ahmed²  Saeed Hamid¹  Khalid Mumtaz¹  Zaigham Abbas¹  Wasim Jafri¹  Shahab Abid¹  Javed Yakoob¹ 

[1] Department of Medicine, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan;Department of Pathology, Aga Khan University, Stadium Road, Karachi, 74800, Pakistan

关键词: Nonulcer dyspepsia;    Recurrence;    Clarithromycin resistance;    Helicobacter pylori;   

Others  :  858166
DOI  :  10.1186/1471-230X-13-33

 received in 2012-10-20, accepted in 2013-02-11,  发布年份 2013

【 摘 要 】

Background

The aim was to investigate the reinfection rate of H. pylori during a follow-up period of 12 months in adults who had undergone eradication therapy.

Methods

One hundred-twenty patients; 116 with gastritis, 3 with duodenal ulcer and 1 gastric ulcer, were studied. Their mean age was 41 ± 13 years (range 18–77) and male: female ratio of 2:1. H. pylori were cultured and antibiotic sensitivity was determined by Epsilometer test (E-test) for clarithromycin (CLR) and amoxicillin (AMX). Primers of urease C gene of H. pylori and Sau-3 and Hha I restriction enzymes were used for polymerase chain reaction-restriction fragment length polymorphism analysis (PCR-RFLP). ¹⁴C urea breath test (¹⁴C-UBT) was performed 4 weeks after the eradication therapy. The successfully treated patients were observed for 12 months with ¹⁴C-UBT to assess H. pylori status. If ¹⁴C-UBT was negative, it was repeated after every 12 weeks. If ¹⁴C-UBT was positive, endoscopy was repeated with biopsies.

Result

The eradication therapy was successful in 102(85%) patients. Out of forty-seven H. pylori isolates cultured, clarithromycin sensitivity was present in 30(64%) and amoxicillin in 45(98%), respectively. Follow-up ¹⁴C-urea breath tests of all 102 patients who eradicated H. pylori remained negative up to 9 months. However, in 6 patients, the ¹⁴C-UBT confirmed recurrence at 12 months. The recurrence rate was 6%.

Conclusion

A low rate of recurrence of H. pylori infection was found in patients with dyspeptic symptoms. H. pylori isolates demonstrated a high invitro clarithromycin resistance.

【 授权许可】

   
2013 Yakoob et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Anon: NIH consensus conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on helicobacter pylori in peptic ulcer disease. JAMA 1994, 272:65-69.
• [2]Sipponen P: Gastric cancer: a long term consequence of H. pylori infection? Scand J Gastroenterol 1994, 29:24-27.
• [3]Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P: Long term follow up of patients treated for helicobacter pylori infection. Gut 2005, 54:1536-1540.
• [4]Kyzekova J, Mour J: The effect of eradication therapy on histological changes in the gastric mucosa in patients with non-ulcer dyspepsia and helicobacter pylori infection. Prospective randomized intervention study. Hepatogastroenterology 1999, 46:2048-2056.
• [5]Larkin CJ, Watson P: Gastric corpus atrophy following eradication of helicobacter pylori. Eur J Gastroenterol Hepatol 2001, 13:377-382.
• [6]Niv Y: H. pylori recurrence after successful eradication. World J Gastroenterol 2008, 14:1477-1478.
• [7]Yakoob J, Hu G, Fan X, Zhang Z: Helicobacter pylori detection in Chinese subjects: a comparison of two common DNA fingerprinting methods. Br J Biomed Sci 2001, 58:239-243.
• [8]Hildebrand P, Bardhan P, Rossi L, Parvin S, Rahman A, Arefin MS, Hasan M, Ahmad MM, Glatz-Krieger K, Terracciano L, Bauerfeind P, Beglinger C, Gyr N, Khan AK: Recrudescence and reinfection with helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology 2001, 121:792-798.
• [9]Bapat MR, Abraham P, Bhandarkar PV, Phadke AY, Joshi AS: Acquisition of helicobacter pylori infection and reinfection after its eradication are uncommon in Indian adults. Indian J Gastroenterol 2000, 19:172-174.
• [10]Najafi M, Sobhani M, Khodadad A, Farahmand F, Motamed F: Reinfection rate after successful helicobacter pylori eradication in children. Iranian J Pediatrics 2010, 2:58-62.
• [11]Jafri W, Yakoob J, Abid S, Siddiqui S, Awan S, Nizami SQ: Helicobacter pylori infection in children: population-based age-specific prevalence and risk factors in a developing country. Acta Paediatr 2010, 99:279-282.
• [12]Morio O, Rioux-Leclercq N, Pagenault M, Corbinais S, Ramee MP, Gosselin M, Bretagne JF: Prospective evaluation of a new rapid urease test (pronto dry) for the diagnosis of helicobacter pylori infection. Gastroenterol Clin Biol 2004, 28:6-7.
• [13]Price AB: The Sydney System: histological division. J Gastroenterol Hepatol 1991, 6:209-222.
• [14]Rasool S, Abid S, Jafri W: Validity and cost comparison of 14 carbon urea breath test for diagnosis of H. pylori in dyspeptic patients. World J Gastroenterol 2007, 13:925-929.
• [15]Van Zwet AA, Thijs C, Kooistra-Smid AM, Schirm J, Snijder JAM: Sensitivity of culture compared with that of polymerase chain reaction for detection of Helicobacter pylori from antral biopsy samples. J Clin Microbiol 1993, 31:1918-1920.
• [16]Labigne A, Cussac V, Courcoux P: Shuttle cloning and nucleotide sequences of helicobacter pylori genes responsible for urease activity. J Bacteriol 1991, 173:1920-1931.
• [17]Fujimoto S, Marshall B, Blaser M: PCR-based restriction fragment length polymorphism typing of helicobacter pylori. J Clin Microbiol 1994, 32:331-334.
• [18]Zhang YY, Xia HH, Zhuang ZH, Zhong J: True re-infection of Helicobacter pylori after successful eradication–worldwide annual rates, risk factors and clinical implications. Aliment Pharmacol Ther 2009, 29:145-160.
• [19]Van der Wouden EJ, Thijs JC, van Zwet AA, Kleibeuker JH: Six-year follow-up after successful triple therapy for helicobacter pylori infection in patients with peptic ulcer disease. Eur J Gastroenterol Hepatol 2000, 13:1235-1239.
• [20]Rollan A, Giancaspero R, Fuster F, Acevedo C, Figueroa C, Hola K, Schulz M, Duarte I: The long-term reinfection rate and the course of duodenal ulcer disease after eradication of helicobacter pylori in a developing country. Am J Gastroenterol 2000, 95:50-56.
• [21]Mitchell HM, Hu P, Chi Y, Chen MH, Li YY, Hazell SL: A low rate of reinfection following effective therapy against helicobacter pylori in a developing nation (china). Gastroenterology 1998, 114:256-260.
• [22]Kim N, Lim SH, Lee KH, Jung HC, Song IS, Kim CY: Helicobacter pylori reinfection rate and duodenal ulcer recurrence in Korea. J Clin Gastroenterol 1998, 27:321-326.
• [23]Xia HH, Talley NJ: Natural acquisition and spontaneous elimination of helicobacter pylori infection. Am J Gastroenterol 1997, 92:1780-1787.
• [24]Xia HH, Talley NJ, Keane CT, O’Morain CA: Recurrence of helicobacter pylori infection after successful eradication: nature, possible causes and potential preventive strategies. Digest Dis Sci 1997, 42:1821-1834.
• [25]Hulten K, Han SW, Enroth H, Klein PD, Opekun AR, Gilman RH, Evans DG, Engstrand L, Graham DY, El-Zaatari FA: Helicobacter pylori in the drinking water in Peru. Gastroenterology 1996, 110:1031-1035.
• [26]Klein PD, Graham DY, Gaillour A, Opekun AR, Smith EO: Water source as risk factor of helicobacter pylori infection in Peruvian children. Lancet 1991, 337:1503-1506.
• [27]Hopkins RJ, Vial PA, Ferreccio C, Ovalle J, Prado P, Sotomayor V, Russell RG, Wasserman SS, Morris JG Jr: Seroprevalence of helicobacter pylori in Chile: vegetable s may serve as one route of transmission. J Infect Dis 1993, 168:222-226.
• [28]Azuma T, Konishi J, Tanaka Y, Hirai M, Ito S, Kato T, Kohli Y: Contribution of HLA-DQA gene to host’s response against helicobacter pylori. Lancet 1994, 343:542-543.
• [29]Sturm AW, van der Pol R, Smits AJ, van Hellemondt FM, Mouton SW, Jamil B, Minai AM, Sampers GH: Over-the-counter availability of antimicrobial agents, self-medication and patterns of resistance in Karachi, Pakistan. J Antimicrob Chemother 1997, 39:543-547.
• [30]Yakoob J, Jafri W, Abid S, Jafri N, Abbas Z, Hamid S, Islam M, Anis K, Shah HA, Shaikh H: Role of rapid urease test and histopathology in the diagnosis of helicobacter pylori infection in a developing country. BMC Gastroenterol 2005, 5:38. BioMed Central Full Text
• [31]Sharara AI, Chedid M, Araj GF, Barada KA, Mourad FH: Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin and tetracycline in Lebanon. Int J Antimicrob Agents 2002, 19:155-158.
• [32]Wu H, Shi XD, Wang HT, Liu JX: Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 2000, 46:121-123.
• [33]Bennett PM: Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacteria. Br J Pharmacol 2008, 153:S347-S357.
• [34]Mégraud F: Resistance of helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997, 11(Suppl 1):43-53.
• [35]Aguilar GR, Ayala G, Fierros-Zárate G: Helicobacter pylori: recent advances in the study of its pathogenicity and prevention. Salud Publica Mex 2001, 43:237-247.
• [36]Sjölund M, Tano E, Blaser MJ, Andersson DI, Engstrand L: Persistence of resistant staphylococcus epidermidis after single course of clarithromycin. Emerg Infect Dis 2005, 11:1389-1393.
• [37]Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F: Risk factors for failure of helicobacter pylori therapy results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003, 17:99-109.
• [38]Graham DY: Antibiotic resistance in helicobacter pylori: implications for therapy. Gastroenterology 1998, 115:1272-1277.
• [39]Houben MH, van de Beek D, Hensen EF, de Craen AJ, Rauws EA, Tytgat GN: A systematic review of helicobacter pylori eradication therapy: the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999, 13:1047-1055.
• [40]Yakoob J, Jafri W, Abbas Z, Abid S, Naz S, Khan R, Khalid A: Risk factors associated with helicobacter pylori infection treatment failure in a high prevalence area. Epidemiol Infect 2011, 139:581-590.